• Elisabeth A Wilde, Ina-Beate Wanner, Kimbra Kenney, Jessica Gill, James R Stone, Seth Disner, Caroline Schnakers, Retsina Meyer, Eric M Prager, Magali Haas, and Andreas Jeromin.
• TBI and Concussion Center, Department of Neurology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
• J. Neurotrauma. 2022 Apr 1; 39 (7-8): 436-457.

AbstractMulti-modal biomarkers (e.g., imaging, blood-based, physiological) of unique traumatic brain injury (TBI) endophenotypes are necessary to guide the development of personalized and targeted therapies for TBI. Optimal biomarkers will be specific, sensitive, rapidly and easily accessed, minimally invasive, cost effective, and bidirectionally translatable for clinical and research use. For both uses, understanding how TBI biomarkers change over time is critical to reliably identify appropriate time windows for an intervention as the injury evolves. Biomarkers that enable researchers and clinicians to identify cellular injury and monitor clinical improvement, inflection, arrest, or deterioration in a patient's clinical trajectory are needed for precision healthcare. Prognostic biomarkers that reliably predict outcomes and recovery windows to assess neurodegenerative change and guide decisions for return to play or duty are also important. TBI biomarkers that fill these needs will transform clinical practice and could reduce the patient's risk for long-term symptoms and lasting deficits. This article summarizes biomarkers currently under investigation and outlines necessary steps to achieve short- and long-term goals, including how biomarkers can advance TBI treatment and improve care for patients with TBI.

11 keywords...

hide…